Position in EXEL
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$3,596,501
+$761,472 QoQ
Shares Held
66,100
0.0% QoQ
Ownership
0.027%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
#203
of 751 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026BRIDGEWAY CAPITAL MANAGEMENT, LLC holds $87,985,615 across 108 Biotechnology names. EXEL ranks #5 (4.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GLUE |
Monte Rosa Therapeutics, Inc.
|
552,566 | $13,372,097 | |
| 2 | INVA |
Innoviva, Inc.
|
350,253 | $7,954,245 | |
| 3 | PBYI |
Puma Biotechnology, Inc.
|
791,616 | $6,420,005 | |
| 4 | RIGL |
Rigel Pharmaceuticals Inc
|
124,184 | $4,858,078 | |
| 5 | EXEL |
Exelixis, Inc.
This page
|
66,100 | $3,596,501 | |
| 6 | CRMD |
CorMedix Inc.
|
434,132 | $3,407,936 | |
| 7 | KROS |
Keros Therapeutics, Inc.
|
265,017 | $2,835,681 | |
| 8 | PTCT |
Ptc Therapeutics, Inc.
|
22,000 | $1,794,540 |
All Filings in EXEL
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,596,501 | 66,100 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $2,835,029 | 66,100 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $3,554,613 | 81,100 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $3,372,145 | 81,650 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $2,851,976 | 64,700 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $2,510,560 | 68,000 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $2,264,400 | 68,000 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||